Table 1.
Correlations between HER2 positivity and clinicopathological features in UUTUC patients who underwent nephroureterectomy (n=171)
| HER2 status | p-value | |||
|---|---|---|---|---|
|
|
||||
| N | Positive | Negative | ||
| Total | 171 | 23 (13.5%) | 148 (86.5%) | |
| Gender | ||||
| Male | 119 | 14 (11.8%) | 105 (8.2%) | p=0.3284 |
| Female | 52 | 9 (17.3%) | 43 (82.7%) | |
| Age | ||||
| Under 70 | 93 | 7 (7.5%) | 86 (92.5%) | p=0.0132 |
| Over 70 | 78 | 16 (20.5%) | 62 (79.5%) | |
| Side | ||||
| Right | 85 | 13 (15.3%) | 72 (84.7%) | p=0.4823 |
| Left | 86 | 10 (11.6%) | 76 (88.4%.) | |
| Previous bladder tumor | ||||
| Present | 31 | 7 (22.6%) | 24 (77.4%) | p=0.0996 |
| Absent | 140 | 16 (11.4%) | 124 (88.6%) | |
| Tumor Stage | ||||
| pTa, pTis, pT1 | 75 | 7 (9.3%) | 68 (90.7%) | p=0.1630 |
| pT2-pT4 | 96 | 16 (16.7%) | 80 (83.3%) | |
| Location of tumor | ||||
| Ureter | 49 | 9 (18.4%) | 40 (81.6%) | p<0.0001 |
| Pelvis | 76 | 0 (0%) | 76 (100%) | |
| Both | 46 | 14 (30.4%) | 32 (69.6%) | |
| Tumor growth | ||||
| Papillary | 126 | 15 (11.9%) | 111 (88.1%) | p=0.3216 |
| Sessile | 45 | 8 (17.8%) | 37(82.2%) | |
| Histological grade | ||||
| Grade 3 | 97 | 21 (21.6%) | 76 (78.4%) | p=0.0003 |
| Non-Grade 3 | 74 | 2 (2.7%) | 72 (97.3%) | |
| Lymphovascular invasion | ||||
| present | 74 | 13 (17.6%) | 61 (82.4%) | p=0.1681 |
| absent | 97 | 10 (10.3%) | 87 (89.7%) | |
| Co-existence of HGCIS | ||||
| Present | 83 | 17 (20.5%) | 66 (79.5%) | p=0.0089 |
| Absent | 88 | 6 (6.8%) | 17 (93.2%) | |
| Lymph node metastasis | ||||
| Present | 19 | 3 (15.8%) | 16 (94.2%) | p=0.7513 |
| Absent | 152 | 20 (13.2%) | 132 (86.8%) | |